Autolus Therapeutics Ltd (AUTL)
Autolus Therapeutics Ltd is a NASDAQ-listed depositary receipt tied to Autolus Therapeutics plc, a clinical-stage biopharmaceutical company focused on T cell therapies for cancer and autoimmune diseases. The company’s pipeline includes several investigational programs in development in the United Kingdom and other international markets. These include obecabtagene autoleucel (AUTO1) for adult ALL, AUTO1/22 for pediatric relapsed or refractory ALL, AUTO4 for peripheral T-cell lymphoma, AUTO6NG for neuroblastoma, and AUTO8 for multiple myeloma. Autolus is also advancing AUTO5, a preclinical TRBC2 program for peripheral T-cell lymphoma. The issuer was incorporated in 2014 and is headquartered in London, United Kingdom.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-AUTL
|
$1.79
|
22.0% Upside
|
Undervalued
|
$8.55
|
481.6% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
July 30, 2026
|
-1.4x
|
3.6x
|
4.2x
|
372.6 M
|
530.9 M
|
49.8%
|
38.6%
|
-5.4
|
—
|
99.3%
|
